Prognostic value of proliferating cell nuclear antigen immunostaining in pediatric rhabdomyosarcomas

Pediatrics International

Volumn 40, Issue 6, 1998, Pages 573-579

  Tokuç, Gülnur ^a   Doǧan, Öner ^b   Ayan, İnci ^a   Kebudi, Rejin ^a   Doǧan, Sema ^a   Demiryont, Misten ^b   çamlica, Hakan ^a  

^a Institute of Oncology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Pediatric rhabdomyosarcoma; Prognostic marker; Proliferating cell nuclear antigen; Proliferating cell nuclear antigen index

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; TUMOR MARKER; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER LOCALIZATION; CANCER SIZE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SURVIVAL ANALYSIS;

EID: 0032438351     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.1998.tb01993.x     Document Type: Article

References (27)

1. Morris Gf, Mathews Mb. Regulation of PCNA during the cell cycle. J. Biol. Chem. 1989; 264: 13 857–4.
2. Waseem Nh, Lane Dp. Monoclonal antibody analysis of PCNA. Structural conservation and the detection of a nucleolar form. J. Cell Set. 1990; 96: 121–9.
3. Mccormick D., Hall Pa. The complexities of PCNA. Histopathology 1992; 21: 591–4.
4. Jaskulski D., Gatti. C., Travali S. et al. Regulation of the PCNA cyclin and thymidine kinase mRNA levels by growth factors. J. Biol. Chem. 1988; 263: 10 175–9.
5. Mathews Mb, Bernstein Rm, Franza Br, Garriels Ji. Identity of the PCNA and cyclin. Nature 1984; 309: 374–6.
6. Ogata K., Ogata Y., Nakamura Rm, Tan Em. Purification and N terminal amino acid sequence of PCNA/cyclin and development of ELISA for anti-PCNA antibodies. J. Immunol. 1985; 135: 2623–7.
7. Ogata K., Kurki P., Celis Je et al. Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication. Exp. Cell Res. 1987; 168: 475–86.
8. 2+ M phase fraction and prognosis. Histopathology 1991; 19: 21–7.
9. Yu Ccw, Fletcher Cdm, Newman Pl et al. A comparison of PCNA immunostaining, nucleolar organizer region (AgNOR) staining and histological grading, in gastrointestinal stromal tumors. J. Pathol 1992; 166: 147–52.
10. Kitomoto M., Nakanishi T., Kira S. et al. The assessment of PCNA immunochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 1993; 72: 1859–65.
11. Klemi Pj, Alanen K., Jalkanen S., Joensuu H. PCNA as a prognostic factor in non-Hodgkin's lymphoma. Br. J. Cancer 1992; 66: 739–43.
12. Oda Y., Hashimoto H., Takeshita S., Tsuneyoshi M. The prognostic value of immunochemical staining for PCNA in synovial sarcoma. Cancer 1993; 72: 478–85.
13. Yu Ccw, Hall Pa, Fletcher Cdm et al. Haemangiopericytoma: The prognostic value of immunohistochemical staining with a monoclonal antibody to PCNA. Histopathology 1991; 19: 29–33.
14. Shimizu T., Usuda N., Yamanda T. et al. Proliferative activity of human thyroid tumors evaluated by proliferative cell nuclear antigen/cyclin immunohistochemical studies. Cancer 1993; 71: 2807–12.
15. Fontanini G., Macchiarini P., Pepe S. et al. The expression of PCNA in paraffin sections of peripheral, node negative, non small cell lung cancer. Cancer 1992; 70: 1520–7.
16. Taylor Cr, Shi Sr, Chaiwun B. et al. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin paraffin sections. Hum. Pathol. 1994; 25: 263–70.
17. Kawasaki H., Mukai K., Yajima S. et al. Prognostic value of PCNA immunostaining in neuroblastoma. Med. Ped. Oncol. 1995; 24: 300–3.
18. Bravo R., Frank R., Blundell Pa, Bravo Hm. Cycylin/PCNA is the auxiliary protein of DNA polymerase delta. Nature 1987; 326: 515–17.
19. Ng Iol, Path Mr, Lai Ec et al. Prognostic significance of PCNA expression in hepatocellular carcinoma. Cancer 1994; 73: 2268–74.
20. Bravo R., Macdonald-Bravo H. Existence of two populations of cyclin/PCNA during the cell cycle. J. Cell Biol. 1987; 105: 1549–54.
21. Von Dierendonck Jh, Keijer R. et al. Cell-cycle-related staining patterns of anti-PCNA monoclonal antibodies. Am. J. Pathol. 1991; 138: 1165–72.
22. Benjamin Dr. PCNA and pediatric tumors. Ped. Pathol. 1991; 11: 507–19.
23. Choong Pf, Akerman M., Willen H. et al. Expression of proliferating cell nuclear antigen and Ki-67 in soft tissue sarcoma. APMIS 1995; 103: 797–805.
24. El-Nagger Ak, Ayala Ag, Abudul-Karim Fw et al. Synovial sarcoma: A DNA flow cytometric study. Cancer 1990; 65: 2295–300.
25. Kroese Mc, Rutgers Dh, Wils Is, Urinik Ja et al. The relevance of the DNA index and proliferation rate in the grading of benign and malignant soft tissue tumors. Cancer 1990; 65: 782–8.
26. Shapiro Dn, Parham Dm, Douglass Md et al. Relationship of tumor cell ploidy to histologic subtype and treatment outcome in children and adolescents with unresectable rhabdomyosarcoma. J. Clin. Oncol. 1991; 9: 159–66.
27. Ueda T., Aozasa K., Tsujimoto M. et al. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989; 63: 1607–11.